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 ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
ceramide containing creams are a safe and effective treatment for patients with atopic dermatitis. 
 
STUDY DESIGN: Review of three randomized controlled studies published in English between 
2009-2016. 
 
DATA SOURCES: Three assessor blind randomized controlled trials found using PubMed and 
EbscoHOST databases. 
 
OUTCOMES MEASURED: Each of the three trials assessed safety and efficacy of a ceramide 
containing cream compared with another method in the treatment of atopic dermatitis. Outcomes 
were measured by Eczema Severity Score (ESS), rating of skin dryness on a 0-4 scale, 
transepidermal water loss (TEWL) measurements, and Severity Scoring for Atopic Dermatitis 
(SCORAD) on a scale of 0-72. 
 
RESULTS: The Marseglia et al1 study showed that subjects using the ceramide containing cream 
had an 84% reduction in their Eczema Severity Score (ESS), compared to the subjects using the 
simple hydrating cream who had a 50% reduction in the ESS. This difference was statistically 
significant as p=0.0001. The Simpson et al2 study showed statistically significant improvements 
in skin dryness, skin hydration and transepidermal water loss (TEWL) in the cream with a 
ceramide precursor as compared to no treatment. The Sugarman et al3 study showed a 50.7% 
decrease (p<0.001) in Severity Scoring for Atopic Dermatitis (SCORAD) when using a ceramide 
formulation. Additionally, it showed no statistically significant difference between the SCORAD 
in the ceramide formulation and fluticasone propionate 0.05%. No serious adverse effects were 
noted in the three studies. 
 
CONCLUSIONS: The results of the three randomized controlled studies show that the use of a 
ceramide containing cream is a safe and effective treatment for atopic dermatitis. Each study 
showed a statistically significant improvement of symptoms without any serious adverse effects.  
 
KEY WORDS: Atopic dermatitis, eczema, ceramide    
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INTRODUCTION 
Atopic dermatitis, or eczema, is a chronic pruritic inflammatory skin disease. It is 
characterized by epidermal changes including spongiosis, acanthosis, hyperkeratosis, and 
lymphhistiocytic infiltrate into the dermis.4 Two cardinal symptoms of atopic dermatitis are 
pruritus and xerosis, but the presentation can vary depending on the patient and severity.4 This 
paper evaluates three randomized controlled trials (RCTs) comparing the efficacy of a ceramide 
containing cream as the treatment for atopic dermatitis as compared with other treatment options. 
Atopic dermatitis is relevant to the Physician Assistant due to the prevalence and cost of 
the disease. Atopic dermatitis effects on average 5% to 20% of children worldwide, and 
approximately 11% of children located in the U.S. Most cases of atopic dermatitis present prior 
to the age of five years old, and there is a female to male ratio of 1.3 to 1. The incidence of 
atopic dermatitis is increasing.4 JAMA Dermatology estimated that adults with eczema had $371 
to $489 higher out-of-pocket costs per person-year compared to those without eczema.6 They 
paid $37 billion and $29 billion in out-of-pocket health care costs in 2010 and 2012, 
respectively.6 Not only are monetary costs of the disease higher; but patients with atopic 
dermatitis are physically visiting their physician more often. In the 2010 National Health 
Interview Survey (NHIS), approximately three of four adults with eczema (six million) had seen 
a physician for their eczema in the previous 12 months.6 In addition, adults with eczema had a 
weighted total of 9.7 million (for 2010) and 7.8 million (for 2012) visits to an urgent care center 
or emergency department in the previous 12 months.6  
The etiology of atopic dermatitis is multifactorial including skin barrier abnormalities, 
defects in innate or adaptive immunity response, and altered skin resident microbial flora.4 
Impaired skin barrier function of intercellular junctions or the stratum corneum, such as 
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deficiency in stratum corneum lipids (ceramides), can lead to increased transepidermal water loss 
(TEWL).4 Increase in TEWL can lead to dryness and severe pruritus, which are the cardinal 
symptoms of atopic dermatitis. Patient presentations of atopic dermatitis can vary based on how 
long symptoms have been present. Acute symptoms include pruritic erythematous papules and 
vesicles which may include crusting or weeping lesions. Chronic atopic dermatitis usually 
presents with scales, excoriation, fissuring, and lichenification of skin. 4 Atopic dermatitis is 
often associated with elevated serum level of IgE as well as a personal or family history of atopy 
(atopic dermatitis, asthma, and allergic rhinitis).4 
Treatment of atopic dermatitis includes a multipronged approach including elimination of 
exacerbating factors, restoration of skin barrier function, hydration of the skin, and 
pharmacologic treatment of skin inflammation.5 Many patients with atopic dermatitis have a 
deficiency in stratum corneum lipids (ceramides), so maintaining skin hydration with thick 
cream, ointment, or moisturizers containing stratum corneum lipids is a key component.5 Lotions 
that have a high water and low oil content can worsen xerosis, where thicker creams (such as 
Eucerin, Cetaphil, Nutraderm) and ointments (such as petroleum jelly, Vaseline, Aquaphor) have 
lower to no water content and can better protect against xerosis.5 Symptoms of pruritus can be 
treated and controlled with antihistamines. Other pharmacologic treatments include topical 
corticosteroids. Typically, low potency for mild symptoms and medium to high potency for 
moderate to severe symptoms. Acute exacerbations may even require a short course of systemic 
glucocorticoids. 5  
The goal of the proposed treatment method is to have a safe and effective role in treating 
atopic dermatitis and reduce the severity of symptoms. This review compares a ceramide 
containing cream with three different treatment options: no treatment, a non-ceramide containing 
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cream, and a topical corticosteroid. The goal of using a ceramide containing cream is to replace 
the deficiency of stratum corneum lipids and potentially reduce or eliminate the need for topical 
or systemic corticosteroid use. The use of ceramide cream has been shown to be a safe and 
effective treatment of atopic dermatitis in those six months to 65 years old. 
 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not ceramide 
containing creams are a safe and effective treatment for patients with atopic dermatitis. 
 
METHODS 
The three studies in this review were randomized controlled trials that met the following 
criteria: the population studied were men and women ages six months to 65 years with atopic 
dermatitis. Interventions included a ceramide containing cream, a moisturizer with ceramide 
precursor, and a ceramide-dominant triple-lipid barrier repair formulation. Comparisons were 
made to a non-ceramide simple hydrating cream, no intervention, and a steroid containing cream 
(fluticasone propionate 0.05% cream). The outcomes measured were decrease in atopic 
dermatitis severity (measured by Eczema Severity Scoring and Severity Scoring for Atopic 
Dermatitis), reduction in skin dryness, and improvement in skin barrier function via reduction in 
trans epidermal water loss (TEWL). 1,2,3 
Keywords used to search for articles consisted of: ceramide, atopic dermatitis, and 
eczema. All articles were published in English in peer-reviewed journals. Articles were 
researched by the author via PubMed and EbscoHOST and selected based on relevance to the 
clinical question that included patient oriented outcomes (POEMs). Inclusion criteria included 
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RCTs published after 2000, men and women aged six months to 65 years with atopic dermatitis, 
and patient oriented evidence that matters (POEMs). Exclusion criteria included articles 
published prior to 2000 and studies focused on disease oriented evidence (DOEs). Statistics 
reported and used include: p-value, relative benefit increase (RBI), absolute benefit increase 
(ABI), control event rate (CER), experimental event rate (EER) and numbers needed to treat 
(NNT). Table 1 displays demographics and characteristics of included studies. 
 
OUTCOMES MEASURED 
All outcomes measured included patient oriented outcomes in the reduction of atopic 
dermatitis symptom severity. The Marseglia et al1 study examined the reduction in eczema 
severity using the Eczema Severity Score (ESS) by blind evaluators clinical observations of 
erythema, induration, edema and lichenification on a 0-3 scale. The Simpson et al2 study 
examined a reduction in skin dryness and improvement in skin barrier function using blind 
evaluators to rate skin dryness on a 0-4 scale and take TEWL measurements at baseline and day 
28. The Sugarman et al3 study examined a decrease in eczema severity using the Severity 
Scoring for Atopic Dermatitis (SCORAD) on a scale of 0-72. 
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Table 1. Demographics and characteristics of included studies  
Study Type #of 
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions  
Marseglia, 
2014 [1] 
Assessor 
blind RCT 
107 6 
months 
to 14 
years  
Children aged 
6 months to 
14 years with 
facial atopic 
eczema 
Severe 
recent atopic 
eczema (<4 
weeks), and 
treatment 
with 
systemic or 
topical 
steroids or 
calcineurin 
inhibitors, 
and presence 
of active 
cutaneous 
bacterial, 
viral, or 
fungal 
infections in 
target areas 
0 A ceramide 
containing 
cream 
(Nutratopic 
Pro-AMP 
cream), 
which also 
contains 
2.5% 
rhamnosoft 
and 2% L-
isoleucine 
(ILE) 
Simpson, 
2013 [2] 
Blind 
evaluator 
RCT 
20 18 
years 
to 65 
years  
Men and 
women ages 
18-65 with 
controlled 
atopic 
dermatitis, 
patients also 
have clinical 
xerotic skin, 
corresponding 
to a score of 
at least 1 on a 
dryness scale 
Pregnant or 
breast 
feeding 
women 
0 Moisturizer 
with 
ceramide 
precursor 
(Cetaphil 
Restoraderm 
Body 
Moisturizer) 
applied 
twice daily 
on one leg 
for 27 days 
Sugarman, 
2009 [3] 
Investigator 
blind 
comparison 
controlled 
RCT 
121 6 
months 
to 18 
years  
Male and 
female 
patients ages 
6 months to 
18 years old 
with 
moderate-to-
severe atopic 
dermatitis 
None listed 5 
(4%) 
Ceramide-
dominant, 
triple-lipid, 
barrier-
repair 
formulation 
(EpiCream 
Skin Barrier 
Emulsion) 
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RESULTS 
All three articles studied the use of a ceramide containing cream as a safe and effective 
treatment for atopic dermatitis. The Marseglia et al1 study compared a ceramide containing 
cream to no intervention, the Simpson et al2 study compared to a non-ceramide containing 
cream, and the Sugarman et al3 study compared with a topical corticosteroid. 
The Marseglia et al1 study examined 107 children aged six months to 14 years with facial 
atopic eczema and excluded children with severe recent atopic eczema, treatment with systemic 
or topical corticosteroids, and presence of active cutaneous infections at target lesions. Subjects 
were randomly assigned to one of two groups, and either applied a ceramide containing cream 
(Nutratopic Pro-AMP cream) or a simple hydrating cream (15% glycerol-based cream containing 
Vaseline 8% and liquid paraffin 2%). Subjects applied the topical treatments to the face two 
times a day for six weeks. Blind evaluators determined subject’s Eczema Severity Score (ESS) at 
baseline, three weeks, and then six weeks. ESS is calculated based on clinical observation of 
erythema, induration, edema, and lichenification of skin. Table 2 displays the ESS at baseline, 
week three and week six. The baseline ESS score for the ceramide containing cream, mean +/- 
standard deviation (SD), was 6.1 +/- 2.5 versus 5.3 +/- 3.0 for the comparison group. At week 6 
the ESS for the ceramide containing cream was 1.0 +/- 1.5, demonstrating an 84% reduction, 
p=0.0001. The comparison group ESS at week 6 was 2.6 +/- 2.0, showing a 50% reduction. The 
ESS mean change from baseline at week 6 was -5.0 points and -2.7 points for the treatment 
group and comparison group respectively. The ESS in the treatment group at week 6 was 
significantly lower than the comparison group (1.0 vs 2.6, CI 95%).1 
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Table 2. Change in ESS for Marseglia et al1 study 
Treatment  Baseline ESS 
(Mean +/- SD) 
Week 3 ESS  
Mean +/- SD 
% reduction 
Week 6 ESS  
Mean +/- SD 
% reduction 
Absolute 
reduction  
(CI 95%) 
Ceramide 
containing cream 
6.1 +/- 2.5 2.5 +/- 2.0 
59% reduction 
1.0 +/- 1.5  
84% reduction 
5.0 points  
(CI: 5.5 to 4.5) 
Simple hydrating 
cream  
5.3 +/- 3.0 3 + 2.0 
42% reduction 
2.6 +/- 2.0  
50% reduction 
2.7 points  
(CI: 3.6 to 1.4) 
 
The Simpson et al2 study examined 20 men and women (excluding pregnant or 
breastfeeding subjects) ages 18-65 with controlled atopic dermatitis and clinical xerotic skin. 
Subjects were given a moisturizer with a ceramide precursor (Cetaphil Restoraderm Body 
Moisturizer, or CRM) and applied it daily on one leg for 28 days. Each subject was also their 
own control, as no treatment was done to the other leg. Blind evaluators assessed level of skin 
dryness on a 0-4 scale, level of skin hydration, and TEWL measurements at baseline and 28 days 
later. Table 3 displays the results. Percentage change in skin dryness from baseline is -55.54% 
and -22.17% for treated area versus non-treated area, p-value <0.001. Percentage change in skin 
hydration from baseline was +117.53% and +25.42% for treated area versus non-treated area 
respectively, p-value <0.001. Percentage change in TEWL from baseline was -30.01% and          
-4.28% for treated area versus non-treated area, p-value = 0.002.2  
Table 3. Results for Simpson et al2 study 
Treatment  % change in skin 
dryness from 
baseline 
% change in skin 
hydration from 
baseline 
% change in 
TEWL from 
baseline 
Moisturizer with 
ceramide precursor 
-55.54% 
 
+117.53% 
 
-30.01% 
 
No treatment  -22.17% +25.42% -4.28% 
p-value p<0.001 p<0.001 p=0.002 
 
 The Sugarman et al3 study examined 121 male and female patients ages six months to 18 
years with moderate to severe atopic dermatitis. Subjects were randomly placed into two 
treatment groups. One group was treated with a ceramide-dominant, triple-lipid, barrier-repair 
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formulation (EpiCream Skin Barrier Emulsion), and the other group was treated with Fluticasone 
proprionate 0.05% cream. Subjects applied the cream to affected areas at approximately the same 
time every day for 28 days. Blind evaluators assessed atopic dermatitis severity using the 
Severity Scoring for Atopic Dermatitis (SCORAD) on a scale of 0-72 at baseline, day 14, and 
day 28. Table 4 displays the percent change from baseline in SCORAD on day 14 and day 28 as 
well as an analysis of variance (ANOVA) comparison. SCORAD mean change from baseline at 
14 days was -36.6% and -50.7% for the ceramide barrier cream and the fluticasone cream groups 
respectively.  SCORAD mean change from baseline at 28 days was -50.7% and -66.7% for 
ceramide barrier cream and the fluticasone cream groups respectively. When comparing the 
change in baseline from the ceramide group to the fluticasone group, the ANOVA p-value was 
0.134. This reveals there is not a statistically significant difference in the outcome between the 
two treatment groups, suggesting the ceramide containing cream would be a safe and effective 
treatment option that could replace fluticasone cream use. When looking solely at the ceramide 
group change from baseline, the -50.7% change is statistically significant as p<0.001.3 
Table 4. Results for Sugarman et al3 study 
Treatment  % change in SCORAD 
from baseline at day 14 
% change in SCORAD 
from baseline at day 28 
Ceramide formulation -36.6% -50.7% 
Fluticasone proprionate 0.05%  -57.6% -66.7% 
ANOVA p-value p=0.021 p=0.134 
 
Sugarman et al3 data was converted to dichotomous; see Tables 5 and 6. Subjects who 
had >75% improvement in SCORAD where considered to have “excellent responses.” At day 14 
the ceramide barrier cream group had five subjects and the fluticasone cream group had 21 
subjects with “excellent responses”. At day 28 the ceramide barrier cream group had 21 subjects 
with “excellent responses” and the fluticasone cream group had 27 subjects. Table 6 shows 
calculations for RBI, ABI, EER, CER, and NNT. NNT was determined to be -14. This means for 
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every 14 people treated with the ceramide cream, one less subject will obtain an “excellent 
response” compared to the fluticasone cream.3 
Table 5. Dichotomous data for Sugarman et al3 study  
Treatment  # people with >75% 
improvement in SCORAD 
on day 14 
# people with >75% 
improvement in SCORAD 
on day 28 
Ceramide formulation 5 21 
Fluticasone proprionate 0.05%  21 27 
 
Table 6. Values for dichotomous data for Sugarman et al3 study  
CER EER RBI ABI NNT 
0.46 0.39 1.84 -0.07 -14 
 
DISCUSSION 
Ceramides are stratum corneum lipids that aid in maintaining skin hydration.5 There are 
no contraindications or black box warnings for the use of ceramides.9 The Cosmetic Ingredient 
Review (CIR) Expert Panel8 reviewed the safety of 23 forms of ceramides and concluded that, 
“the following ceramide ingredients are safe in cosmetics in the present practices of use and 
concentration described in this safety assessment.”8 An article in the Journal of Food and 
Chemical Toxicology further expanded on the CIR Expert Panel conclusions and discovered, 
“there may be sufficient margin of safety for systemic toxicity to humans if ceramide 3 is used 
less than 1% as an ingredient for cosmetic products.”7  
The Marseglia et al1 and Simpson et al2 studies did not display any adverse effects from 
the use of ceramide cream. In the Sugarman et al3 study, while there were no serious adverse 
events attributed to the agents studied, there were four subjects in the ceramide formulation 
group who initially worsened and required “rescue therapy” with fluticasone use. The adverse 
effects mimicked the subject’s original disease (atopic dermatitis), so the authors did not attribute 
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the initial increase in severity of symptoms as directly caused by the ceramide formulation, but 
rather as “disease flares”.3  
Limitations to the Marseglia et al1 study and the Simpson et al2 study include that it was 
not double blinded. The subjects in the Marseglia et al1 study could tell which cream (ceramide 
containing or basic glycerol based) they were using. The subjects in the Simpson et al2 study 
where their own control as they applied cream to one leg and not the other. In both studies this 
was corrected for by having blind assessors evaluate the patients. Limitations to the Sugarman et 
al3 study include that the subjects were not blinded, there was no placebo group, hydrocortisone 
was substituted for some subjects, and five patients dropped out of the study. The subjects could 
not be blinded as many had used fluticasone cream 0.05% before and knew the consistency. 
There was no placebo group because the investigators deemed it unethical not to treat pediatric 
patients with moderate to severe atopic dermatitis, so no subjects were left without treatment. 
The investigators also substituted hydrocortisone cream 2.5% for the fluticasone cream 0.05% if 
patients needed to use it on their face or intertriginous areas. Lastly, five patients either dropped 
out of the study or were lost to follow up. 
 
CONCLUSION 
The results of the three randomized controlled trials in this selective EBM review 
conclude that ceramide containing creams are a safe and effective treatment for atopic dermatitis. 
All three studies showed a statistically significant reduction in atopic dermatitis symptoms after 
the use of a ceramide containing cream. Additionally, the Sugarman et al3 study showed there is 
no statistical difference between the ceramide dominant barrier cream and the fluticasone 
formula after 28 days of treatment of moderate-to-severe atopic dermatitis. This is advantageous 
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for pediatric patients who should not use steroid creams long term on their face. The ceramide 
cream can decrease the need for topical steroids. Future studies should examine combination 
therapy of a ceramide cream with a steroid cream. This type of research could also analyze the 
efficacy of ceramide creams being used for a longer duration as a maintenance or preventive 
therapy. In conclusion, this systematic review shows that ceramide containing creams are a safe 
and effective treatment for symptoms of atopic dermatitis.
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